ClinicalTrials.gg
RecruitingNCT07466173Updated Nov 16, 2026

The Importance of Insulin Action in the Brain for the Immune System During Physical Activity-Overweight

An interventional study of Spiroergometer test with intranasal insulin spray and Spiroergometer test with intranasal placebo spray in Insulin Sensitivity, sponsored by University of Ulm. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by University of Ulm · Not applicable, Interventional, and Basic science

How we know

Updated Nov 16, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 92 studies in Insulin Resistance with a site in Germany — 17 open to participants now, 20 under way, none of them phase 3. Insulin Resistance · Germany.

Planned enrollment
75th of 78
8 · median 37
Started
2026
with 1 other
No phase
44 of 92
9 open now
Primary completion
2027-06
later than 10 of 19 live
Registered
91st of 92
by date
Lead sponsor
4 of 92
University of Ulm

Among the 92 studies in Insulin Resistance with a site in Germany, this one is the 75th largest by planned enrollment of the 78 interventional ones that give a count, is one of 2 that started in 2026, is one of 44 with no phase, reaches primary completion later than 10 of the 19 other live ones, and was the 91st registered.

Insulin Resistance

2,974 studies on the registry are indexed under Insulin Resistance; 336 are open to participants now.

Browse Insulin Resistance studies →

Open to participants now

17 of the 92 studies in Insulin Resistance with a site in Germany are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 241 Insulin Resistance studies recruiting now, 52 (22%) set no upper age limit and 157 (65%) stop at 75 or younger; 28 take children under 18; 112 take healthy volunteers.

This study: 18 Years to 30 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Insulin Resistance with a site in Germany, or all of them as a file.
02

Study summary

The goal of this clinical trial is to clarify the interaction of central insulin action and physical activity with the immune system. Therefore, participants will undergo bicycle spiroergometer tests. This approach will be compared between days with insulin delivery to the brain as nasal spray and days with placebo spray. In another trial (NCT06552130) lean participants already have been tested. Significant effects on circulating cytokines could be identified. In this amendment, overweight persons in which brain insulin resistance is expected will be tested.

Read the detailed description

This research project aims to investigate if the brain insulin action regulates the immune system via the autonomous nervous system during physical activity and investigate whether participants with overweight respond different compared to lean persons. The lean persons were already studied in another trial (NCT06552130) and this trial serves as an amendment.

Insulin action in the brain will be introduced by application of insulin as nasal spray (on one day) versus carrier solution as placebo nasal spray (on another day) in a randomized, blinded fashion. Spray administration will be performed 30 minutes before a 60 min bicycle spiroergometer test at 70 % VO2max that will introduce a postprandial state. On placebo day, the known spillover of tiny amounts of nasal insulin into the systemic circulation will be mimicked by an appropriate i.v. insulin bolus. Using this approach, brain-derived regulation of the immune system including the stimulation of immune cells via cytokines, physical performance, activity of the autonomous nervous system and gene-expression of leukocytes will be examined.

03

Conditions studied

  • Insulin Sensitivity

Keywords

  • brain insulin action
  • autonomic nervous system
  • physical activity
  • immune system
04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • > 28 kg/m2
  • no known primary disease
  • hormonal with a single-phase preparation

Exclusion criteria

Exclusion Criteria:

  • alcohol or drug abuse
  • At screening: \< 12 g/dl for women and Hb \< 14 g/dl for men
  • Any (clinical) condition that would endanger participant's safety or question scientific success according to a physician's opinion.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    Intranasal Insulin Spray

    160 Units of human insulin as nasal spray

    Other: Spiroergometer test with intranasal insulin spray

  • Placebo comparator
    Placebo Spray

    Nasal spray containing placebo solution

    Other: Spiroergometer test with intranasal placebo spray

Interventions

  • OtherSpiroergometer test with intranasal insulin spray

    Participants will undergo a 60 min bicycle spiroergometer test and intranasal insulin spray. Intranasal insulin will be administered 30 minutes prior to the start of the physical activity.

  • OtherSpiroergometer test with intranasal placebo spray

    Participants will undergo a 30 min bicycle spiroergometer test and intranasal placebo spray. To mimic insulin spill-over from nasal spray into systemic circulation, an i.v. insulin bolus of 3 mU × kg-1. will be administered over 15 minutes 30 minutes prior to the start of the physical activity on the placebo spray day. On the insulin spray day a comparable amount of saline will be infused.

06

What researchers measure

Primary outcomes

  1. Immune system activation

    Influence of central nervous insulin action on the activation of the immune system activation by exercise, measured by circulating cytokines and cytokines in the supernatant of stimulated peripheral blood mononuclear cells.

    Time frame: 120 minutes

Secondary outcomes

  1. Maximal oxygen consumption (VO2max)

    Influence of central nervous insulin action on physical performance measured as VO2 peak during spiroergometry.

    Time frame: 60 minutes

  2. Heat rate variability

    Influence of central nervous insulin action on the activity of the autonomic nervous system recorded by means of heart rate variability from an electrocardiogram.

    Time frame: 120 minutes

  3. Corticotropic pituitary axis modulation

    Corticotropic pituitary axis modulation Influence of central nervous insulin action in the activity of the corticotropin pituitary axis during physical activity, measured by cortisol, dehydroepiandrosterone and adrenocorticotropic hormone

    Time frame: 120 minutes

  4. Leukocyte gene expression

    Influence of central nervous insulin action on the gene expression of leukocytes during physical activity

    Time frame: 120 minutes

  5. Individual anaerobic threshold

    Influence of central nervous insulin action on physical performance. Individual anaerobic threshold assessed by lactate measurement from venous blood sampling.

    Time frame: 120 minutes

  6. Catecholamines

    Influence of central nervous insulin action on the activity of the autonomic nervous system recorded by means of measuring catecholamine concentrations from venous blood.

    Time frame: 120 minutes

  7. Effects on blood coagulation parameters

    Influence of central nervous insulin action and/or physical activity on blood coagulation parameters assessed through global coagulation tests and single coagulation factors.

    Time frame: 120 minutes

Other outcomes

  1. Sex differences

    Potential differences in the above mentioned outcomes between sexes will be analyzed.

    Time frame: 120 minutes

  2. Differences between lean and overweight persons

    Potential differences in the above mentioned outcomes between lean individuals studied in (NCT06552130) and overweight individuals studied in this trial.

    Time frame: 120 minutes

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Jun 2027, 7 months after the start.

Of 715 non-industry interventional studies with no phase under Insulin Resistance, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 7 months is below that.

Counting every sponsor, half of 755 studies reached it within 21 months; a quarter within 9 and three quarters within 40.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: start Apr 2026 → Nov 2026, primary completion Dec 2026 → Jun 2027 and completion Jun 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2026
First posted
Mar 12, 2026
StartActual
Nov 2, 2026was Apr 2026
Primary completionEst.
Jun 2027was Dec 2026
CompletionEst.
Dec 2027was Jun 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 16, 2026
Sites
Ulm University Hospital is now Recruiting
Nov 16, 2026
Start date
Apr 2026→Nov 2, 2026 (actual)
Nov 16, 2026
Primary completion
Dec 2026→Jun 2027
Nov 16, 2026
Study completion
Jun 2027→Dec 2027
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Not yet recruiting→Recruiting
    Ulm University Hospital is now Recruiting
    Start date Apr 2026→Nov 2, 2026 (now actual)
    Primary completion Dec 2026→Jun 2027
    Study completion Jun 2027→Dec 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07466173
Lead sponsor
University of Ulm
Responsible party
Martin Heni (Head of the Section Endocrinology and Diabetology, Full Professorship (W3) for Endocrinology and Diabetology, University of Ulm) — Principal investigator
First posted
Mar 12, 2026
Start date
Nov 2, 2026
Primary completion
Jun 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Martin Heni, MD
Contact
martin.heni@uniklinik-ulm.de
+4973150044505
Sabrina Wangler
Contact
sabrina.wangler@uniklinik-ulm.de
+4973150044782
Martin Heni, MD
principal investigator · University of Ulm

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion